Enterprise Value
-40.03M
Cash
102.2M
Avg Qtr Burn
-17.38M
Short % of Float
9.84%
Insider Ownership
3.94%
Institutional Own.
59.25%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BDC-1001 +/- pertuzumab Details HER2-expressing cancers | Phase 2 Data readout | |
BDC-3042 Details Cancer, Solid tumor/s | Phase 1/2 Data readout |